Skip to main content
. 2015 Nov 30;40(4):359–365. doi: 10.1016/j.jgr.2015.11.003

Fig. 3.

Fig. 3

Effects of ginsenoside Ro (G-Ro) on vasodilator-stimulated phosphoprotein (VASP) phosphorylation. (A) Effects of G-Ro on VASP phosphorylation. Lane 1, intact platelets (base); Lane 2, thrombin (0.05 U/mL); Lane 3, thrombin (0.05 U/mL) + G-Ro (100μM); Lane 4, thrombin (0.05 U/mL) + G-Ro (200μM); and Lane 5, thrombin (0.05 U/mL) + G-Ro (300μM). (B) The ratio of phosphorylation of VASP (Ser157)-50 kDa to β-actin by G-Ro. Its ratio is from Fig. 3A. (C) Effects of G-Ro on VASP (Ser239)-50 kDa phosphorylation. Lane 1, intact platelets (base); Lane 2, thrombin (0.05 U/mL); Lane 3, thrombin (0.05 U/mL) + G-Ro (100 μM); Lane 4, thrombin (0.05 U/mL) + G-Ro (200μM); Lane 5, thrombin (0.05 U/mL) + G-Ro (300 μM); and Lane 6, thrombin (0.05 U/mL) + 8-Br-cGMP (1mM). (D) Effects of G-Ro on VASP (Ser157)-50 kDa phosphorylation in the presence of an A-kinase inhibitor (Rp-8-Br-cAMPS). Lane 1, intact platelets (base); Lane 2, thrombin (0.05 U/mL); Lane 3, thrombin (0.05 U/mL) + G-Ro (300μM); Lane 4, thrombin (0.05 U/mL) + G-Ro (300μM) + Rp-8-Br-cAMPS (250 μM); and Lane 5, thrombin (0.05 U/mL) + pCPT-cAMP (1mM). Western blotting was performed as described in the “Materials and methods” section. Data are presented as mean ± SD (n = 4). * p < 0.05 versus the thrombin-stimulated human platelets. ** p < 0.05 versus the thrombin-stimulated human platelets in the presence of G-Ro (300μM).